Logo image of EVAX

EVAXION A/S (EVAX) Stock Fundamental Analysis

USA - NASDAQ:EVAX - US29970R3030 - ADR

5.43 USD
+0.69 (+14.56%)
Last: 10/3/2025, 8:00:02 PM
5.2601 USD
-0.17 (-3.13%)
After Hours: 10/3/2025, 8:00:02 PM
Fundamental Rating

2

Overall EVAX gets a fundamental rating of 2 out of 10. We evaluated EVAX against 536 industry peers in the Biotechnology industry. EVAX may be in some trouble as it scores bad on both profitability and health. EVAX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

EVAX had negative earnings in the past year.
In the past year EVAX has reported a negative cash flow from operations.
EVAX had negative earnings in each of the past 5 years.
EVAX had a negative operating cash flow in each of the past 5 years.
EVAX Yearly Net Income VS EBIT VS OCF VS FCFEVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -53.34%, EVAX is in line with its industry, outperforming 47.95% of the companies in the same industry.
EVAX has a Return On Equity of -192.34%. This is in the lower half of the industry: EVAX underperforms 66.42% of its industry peers.
Industry RankSector Rank
ROA -53.34%
ROE -192.34%
ROIC N/A
ROA(3y)-120.5%
ROA(5y)-109.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVAX Yearly ROA, ROE, ROICEVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EVAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EVAX Yearly Profit, Operating, Gross MarginsEVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

3

2. Health

2.1 Basic Checks

EVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EVAX has been increased compared to 1 year ago.
EVAX has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, EVAX has an improved debt to assets ratio.
EVAX Yearly Shares OutstandingEVAX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
EVAX Yearly Total Debt VS Total AssetsEVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -0.30, we must say that EVAX is in the distress zone and has some risk of bankruptcy.
EVAX has a Altman-Z score of -0.30. This is comparable to the rest of the industry: EVAX outperforms 57.65% of its industry peers.
EVAX has a Debt/Equity ratio of 1.73. This is a high value indicating a heavy dependency on external financing.
EVAX has a worse Debt to Equity ratio (1.73) than 79.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.73
Debt/FCF N/A
Altman-Z -0.3
ROIC/WACCN/A
WACC5.54%
EVAX Yearly LT Debt VS Equity VS FCFEVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

A Current Ratio of 3.42 indicates that EVAX has no problem at all paying its short term obligations.
EVAX has a Current ratio of 3.42. This is in the lower half of the industry: EVAX underperforms 60.45% of its industry peers.
EVAX has a Quick Ratio of 3.42. This indicates that EVAX is financially healthy and has no problem in meeting its short term obligations.
EVAX has a Quick ratio of 3.42. This is comparable to the rest of the industry: EVAX outperforms 41.04% of its industry peers.
Industry RankSector Rank
Current Ratio 3.42
Quick Ratio 3.42
EVAX Yearly Current Assets VS Current LiabilitesEVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

EVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.02%, which is quite impressive.
The Revenue has grown by 1042.45% in the past year. This is a very strong growth!
EPS 1Y (TTM)76.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.67%
Revenue 1Y (TTM)1042.45%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-75.97%

3.2 Future

EVAX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.29% yearly.
Based on estimates for the next years, EVAX will show a very strong growth in Revenue. The Revenue will grow by 61.85% on average per year.
EPS Next Y-2.61%
EPS Next 2Y13.99%
EPS Next 3Y27.05%
EPS Next 5Y15.29%
Revenue Next Year-80.61%
Revenue Next 2Y0.95%
Revenue Next 3Y118.03%
Revenue Next 5Y61.85%

3.3 Evolution

EVAX Yearly Revenue VS EstimatesEVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M
EVAX Yearly EPS VS EstimatesEVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EVAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVAX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVAX Price Earnings VS Forward Price EarningsEVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVAX Per share dataEVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

EVAX's earnings are expected to grow with 27.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.99%
EPS Next 3Y27.05%

More info and screens

0

5. Dividend

5.1 Amount

EVAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVAXION A/S

NASDAQ:EVAX (10/3/2025, 8:00:02 PM)

After market: 5.2601 -0.17 (-3.13%)

5.43

+0.69 (+14.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)10-29 2025-10-29
Inst Owners1.91%
Inst Owner Change-15.19%
Ins Owners0.68%
Ins Owner ChangeN/A
Market Cap34.30M
Analysts82.5
Price Target11.22 (106.63%)
Short Float %3.16%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)60.81%
Min EPS beat(2)24.59%
Max EPS beat(2)97.03%
EPS beat(4)4
Avg EPS beat(4)54.87%
Min EPS beat(4)11.56%
Max EPS beat(4)97.03%
EPS beat(8)7
Avg EPS beat(8)54.84%
EPS beat(12)10
Avg EPS beat(12)37.39%
EPS beat(16)13
Avg EPS beat(16)31.2%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)83.33%
PT rev (3m)-65.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.47%
EPS NY rev (1m)-26.59%
EPS NY rev (3m)-10.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.8
P/FCF N/A
P/OCF N/A
P/B 5.51
P/tB 5.51
EV/EBITDA N/A
EPS(TTM)-4.22
EYN/A
EPS(NY)-1.96
Fwd EYN/A
FCF(TTM)-1.85
FCFYN/A
OCF(TTM)-1.85
OCFYN/A
SpS0.5
BVpS0.99
TBVpS0.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.34%
ROE -192.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.5%
ROA(5y)-109.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 1.73
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.42
Quick Ratio 3.42
Altman-Z -0.3
F-Score6
WACC5.54%
ROIC/WACCN/A
Cap/Depr(3y)21.76%
Cap/Depr(5y)127.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.67%
EPS Next Y-2.61%
EPS Next 2Y13.99%
EPS Next 3Y27.05%
EPS Next 5Y15.29%
Revenue 1Y (TTM)1042.45%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-75.97%
Revenue Next Year-80.61%
Revenue Next 2Y0.95%
Revenue Next 3Y118.03%
Revenue Next 5Y61.85%
EBIT growth 1Y26.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.7%
OCF growth 3YN/A
OCF growth 5YN/A